The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients

Authors :: Stellbrink, Hj
Rugina, S
Zagler, C
Esser, S
Castagna, A
Gazzard, B
Hill, A
Delft, Y
Marks, S
Source :: Journal of the International AIDS Society. November, 2010, Vol. 13, p47, 1 p.
Publication Year :: 2010
Abstract: 7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK<br />Background Efavirenz (EFV) treatment is associated with a range of neuropsychiatric (NPS) adverse events (AEs), which differ in duration and severity. Methods In this double‐blind placebo‐controlled trial, 157 treatment‐naïve patients [...]

Subjects :: Neurologic manifestations of general diseases -- Diagnosis -- Care and treatment
Efavirenz -- Dosage and administration -- Complications and side effects
HIV infection -- Development and progression -- Care and treatment
Health

Full Text Access

Tools